PATENT CLAIM ANALYSIS

Application Number: 15764781
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "001000"]

Abstract:
The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.

Claim (Index 24):
The method of  claim 23 , wherein the XTCi is selected from the group of sulfasalazine and erastin.

Metadata:
- Claim Count in Document: 47.0
- Percentile: 90.0
- Lexical Diversity: 1.65116
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15023229', '15580991', '15160729', '14770994', '14094042']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.829073826689816
- 35 USC 102 Novelty (BERT): 0.5602712045546063
- Combined Prediction Score: 0.8021935644762951
- Mean Citation Score: 448.78333
- Max Citation Score: 526.1375
- Similarity Product: 297.6007633417845

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test